NVCR News and Press, NovoCure Limited From 01/05/23

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: CHIARI VFX / Shutterstock Huadi International (NASDAQ: HUDI ) stock is climbing higher on Thursday even without specific news from the Chinese steel company. What appears to be behind today’s moveme...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: shutterstock.com/ZinetroN Magic Empire Global (NASDAQ: MEGL ) stock is rocketing higher on Thursday despite a lack of news from the Hong Kong financial services provider. Instead, it looks like speculation...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips What’s driving the NovoCure (NASDAQ: NVCR ) stock price by more than 50% today? The big news concerns NovoCure’s proposed treatment for a particular type of lung cancer. A clinical study has met its primary en...

Shares of Novocure (NASDAQ: NVCR) are skyrocketing 49.8% higher as of 10:12 a.m. ET on Thursday. The huge jump came after the company announced the results from a late-stage clinical study evaluating its Tumor Treating Fields (TTFields) therapy in treating stage 4 non-small cell lung canc...

The stock market remained volatile on Thursday, with investors reacting negatively to signs that the economy might be too strong for the Federal Reserve to slow the pace of its interest rate increases. After having been slightly higher earlier in the morning, the Nasdaq Composite (NASDAQIND...

U.S.-based health equipment developer NovoCure Limited ( NASDAQ: NVCR ) and Chinese biotech Zai Lab Limited ( NASDAQ: ZLAB ) announced Thursday that their pivotal Phase 3 trial for Tumor Treating Fields (TTFields) met the primary endpoint in non-small cell lung cancer (NSCLC). ...

The LUNAR study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in overall survival The full LUNAR data will be presented at a future medical congress SHANGHAI and CAMBRIDGE, Mass. and ROOT, Switzerland, Jan. 05, 2023 (GLOB...

The LUNAR study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in overall survival The full LUNAR data will be presented at a future medical congress Novocure (NASDAQ: NVCR) today announced the LUNAR study met its primar...

Summary ARK Invest does great deep-dive research. Utilize their insights along with market timing considerations to generate alpha. The performance of ARKG is dictated mostly by interest rate decisions in the current environment. But underneath the macro layer, there are many promising ...

Novocure (NASDAQ: NVCR) announced today it will participate in the 41 st Annual J. P. Morgan Healthcare Conference on January 10-11, 2023. William Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and address questions from analysts at 7:30 a.m. PST on January 1...